Schedule of Events

Welcome Address 
Marina Garassino, MD, University of Chicago, Chicago

Major Questions Facing us in 2021
Moderator: David Carbone, MD, PhD, The Ohio State University, Columbus, Ohio [M]

• Patient Perspective: Unmet Needs Moving Forward
  • ​Jennifer King, PhD, GO2 Foundation for Lung Cancer, San Carlos, California [Patient Advocate]
• Non-small Cell Lung Cancer: Questions Raised by Recent Clinical Trials
  • ​Walter J. Curran Jr. MD, FACR, FASCO, GenesisCare, Atlanta [R]
• Managing Early Stage Lung Cancer: Optimal Management and Evolving Approaches
  • ​Linda W. Martin, MD, MPH, University of Virginia, Charlottesville, Virginia [S]
• Small Cell Lung Cancer: Breakthroughs and Unresolved Controversies
  • ​Gregory P. Kalemkerian, MD, University of Michigan, Ann Arbor, Michigan [M]
• Mesothelioma and Thymic Cancer: Promising Leads in Rare Diseases
  • ​Patrick Forde, MBBCh, Johns Hopkins University, Baltimore [M]
• Q&A

Coffee Break in Exhibit Hall

Hot Topic: Definitions and Optimal Management of Oligometastatic Disease
Moderator: Percy Lee , MD, MD Anderson Cancer Center, Houston [R]

• Medical Oncology Perspective
  • ​Joel Neal, MD, PhD, Stanford University, Stanford, California [M]
• Radiation Oncology Perspective
  • ​Puneeth Iyengar, MD, PhD, UT Southwestern Medical Center, Dallas [R]
• Surgical Oncology Perspective
  • ​Mara Antonoff, MD, FACS, MD Anderson Cancer Center, Houston [S]
• Case-based Discussion and Q&A

Overcoming Obstacles in Oncology - Session 1: Neoadjuvant Therapies and Toxicity Challenges
Moderator: Vickie Shannon, MD, MD Anderson Cancer Center, Houston [Pulmonologist]

Table Topics:

• Toxicity Challenges
  • Sandip Patel, MD, University of California San Diego, San Diego [M]
• Neoadjuvant Immunotherapy
  • ​Linda W. Martin, MD, MPH, University of Virginia, Charlottesville, Virginia [S]
  • David Carbone, MD, PhD, The Ohio State University, Columbus, Ohio [M]

Overcoming Obstacles in Oncology - Session 2: Multidisciplinary Management of Brain Metastases in the Era of Effective Medical Therapies
Moderator: Ticiana Leal, MD, Winship Cancer Institute of Emory University, Atlanta[M]

Table Topics: 

• When to do TKIs, SRS or Local Therapy in the Brain
  • ​Kristin Higgins, MD, Winship Cancer Institute of Emory University, Atlanta[R]
• When to use SRS vs. Hippocampal Avoidance WBI
  • ​Vinai Gondi, MD, Northwestern Medicine, Chicago [R]
• Differentiating Radiation Necrosis from Progression
  • Joshua Palmer, MD, The Ohio State University [R]

• A Nested Case-Control Study of Lung Cancer for Immune Biomarkers
  • Umayal Sivagnanalingam, BS, MS, University of Pittsburgh School of Medicine, Pittsburgh
• Use of AVATS, Awake Video Assisted Thoracic Surgery, to Redefine Operability in Lung Cancer Patients with Extremely Poor Pulmonary Function
  • Ara Klijian, MD, Sharp & Scripps Hospital Systems, San Diego
• Toxicity and Survival Outcomes from Intensity Modulated Proton Therapy-based Re-irradiation in Patients with Non-small Cell Lung Cancer
  • Pranshu Mohindra, MD, MBBS, University of Maryland School of Medicine, Baltimore
• Timeliness of Lung Cancer Care from the Point of Suspicious Image at an Urban Safety Net Hospital by Demographic and Clinical Factors
  • Noreen Siddiqi, MS, Boston U

Distinguishing Response from Cancer Progression  
Moderator: Sue Yom, MD, PhD, University of California, San Francisco, San Francisco [R]

• Surveillance Imaging for Lung Cancer
  • Sharyn Katz, MD, MTR, University of Pennsylvania, Philadelphia [Radiologist]
• Distinguishing Progression from Response After SBRT
  • ​Megan Daly, MD, University of California, Davis, Sacramento, California [R]
• Immunotherapy: Pseudoprogression, Hyperprogression or Progression?
  • ​Sandip Patel, MD, University of California, San Diego, San Diego [M]
• Q&A

Complex Topics in Immunotherapy
Moderator: Vickie Shannon, MD, MD Anderson Cancer Center, Houston [Pulmonologist]

• Operating During and After Immunotherapy
  • ​Jessica Donington, MD, MSCR, University of Chicago, Chicago [S]
• Combining IO and RT
  • ​Salma Jabbour, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey [R]
• IO Rechallenge After Prior Immunotherapy or Immune Toxicity
  • ​Christine Bestvina, MD, University of Chicago, Chicago [M]
• Patient Selection: Driver Mutations and Biomarker or Clinical Subsets
  • ​Julia Rotow, MD, Dana-Farber Cancer Institute, Boston [M]
• Q&A

Coffee Break and Research Feature in Exhibit Hall

Overcoming Obstacles in Oncology - Session 3: Frailty and Poor Performance Status Patients
Moderator: Carolyn Presley, MD, The Ohio State University, Columbus, Ohio [M]

Table Topics:

• The Role of Dementia
  • Carolyn Presley, MD, The Ohio State University, Columbus, Ohio [M]
• Screening for Measurements of Fraility and Mitigation for Faility
  • Mark K. Ferguson, MD, University of Chicago, Chicago [S]

Overcoming Obstacles in Oncology - Session 4: Optimizing Survivorship 
Moderator: Ticiana Leal, MD, Winship Cancer Institute of Emory University [M]

Table Topics: 

• Chronic Issues from Systemic Therapy
  • ​Salma Jabbour, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey [R]
• Financial Toxicity
  • ​Fumiko Chino, MD, Memorial Sloan Kettering Cancer Center, New York [R]
• Smoking Cessation and Optimizing Pulmonary Function
  • ​Vickie Shannon, MD, MD Anderson Cancer Center, Houston [Pulmonologist]

Challenging Cases in the Clinic
Moderator: Jeffrey Bradley, MD, FASTRO, Emory University School of Medicine, Atlanta [R]
 
Panelists:

• Megan Daly, MD, University of California, Davis, Sacramento, California [R]
• Mark K. Ferguson, MD, University of Chicago, Chicago [S]
• Ticiana Leal, MD, Winship Cancer Institute of Emory University [M]
• Vickie Shannon, MD, MD Anderson Cancer Center, Houston [Pulmonologist]

Lunch and Poster Viewing in the Exhibit Hall

Early-career and Trainee Networking Luncheon: Launching Your Successful Career

• How to Get Your Paper Published
  • ​Sue Yom, MD, PhD, FASTRO, University of California, San Francisco
• Finding Personal/Professional Balance
  • Kristin Higgins, MD, Winship Cancer Institute, Emory University, Atlanta
• Seeking Out and Maintaining Mentoring Relationships
  • Percy Lee, MD, MD Anderson Cancer Center, Houston, Texas [R]

• Comparison of National Comprehensive Cancer Network and American College of Surgeons Commission on Cancer Lymph Node Sampling Guidelines for Non-small Cell Lung Cancer
  • Brendan Heiden, MD, MPHS, Washington University School of Medicine, St. Louis
• Impact of Mesothelioma Histologic Subtype and Use of Cancer-directed Surgery on Outcomes in the National Cancer Database
  • Arian Mansur, BA, Massachusetts General Hospital, Boston
• Toxicity and Survival Outcomes from Intensity Modulated Proton Therapy-based Re-irradiation in Patients with Non-Small Cell Lung Cancer
  • Pranshu Mohindra, MD, MBBS, University of Maryland School of Medicine, Baltimore
• Hot Spot Not Hot Enough? Differences in Local Control for Non-small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy Based on Maximum Point Dose within the Planning Target Volume
  • Erica L. Braschi, BS, University of Florida College of
    Medicine, Gainesville, Florida
• Prospective Evaluation of Limited Stage Small Cell Lung Cancer (LS-SCLC) Fractionation Regimen Usage and Toxicity in a Large Statewide Quality Collaborative
  • Steven Allen, MD, PhD, University of Michigan, Ann Arbor, Michigan
• Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
  • Mirek Fatyga, PhD, Mayo Clinic Arizona, Phoenix
• FLT-PET/CT in Non-small Cell Lung Cancer treated with SBRT- A Pilot Study
  • Shirley Lewis, MD, DNB, FRCR, University of Toronto, Toronto, Canada
• Tepotinib in Patients with Advanced NSCLC with MET Amplification (METamp)
  • Xiuning Le, MD, University of Texas, MD Anderson Cancer Center, Houston, Texas

Hot Topic: Precision Diagnostics
Moderator: Kurt Schalper, MD, PhD, Yale School of Medicine, New Haven, Connecticut [Pathologist]

• Molecular Diagnostics: Who, Which, When, Why, and How
  • ​Lynette Sholl, MD, Brigham and Women’s Hospital, Boston [Surgical Pathologist]
• Why to Wait for Molecular Results Before Initiating Therapy 
  • Shirish Gadgeel, MD, Henry Ford Health System, Detroit [M]
• Types of Liquid Biopsies and When to Use Them 
  • ​Maximilian Diehn, MD, PhD, Stanford University, Stanford, California [R]
• Future Directions in Molecular Diagnostics: IO Biomarkers, STK11
  • ​Kurt Schalper, MD, PhD, Yale School of Medicine, New Haven, Connecticut [Pathologist]
• Q&A

• Screening and How Imaging/Staging Availability Affects Survival
  • ​Douglas Arenberg, MD, University of Michigan, Ann Arbor, Michigan [Pulmonologist]
• Diagnostics 
  • ​Claudia Henschke, MD, PhD, Mount Sinai Hospital, New York [Radiologist]
• Staging
  • ​Brendon Stiles, MD, Montefiore-Einstein Cancer Center, New York [S]
•  Q&A

Welcome Address 
David Carbone, MD, PhD, The Ohio State University, Columbus, Ohio [S]

Beyond the Clinic: Community Impacts 
Moderator: Marina Garassino, MD, University of Chicago, Chicago [M]

• Social Media Use in Medicine
  • Howard (Jack) West, MD, City of Hope, Duarte, California [M]
• Equity in Medicine
  • ​Narjust Duma, MD, Dana-Farber Cancer Institute, Boston [M]
• Wildfires and Climate Change: Effects on Lung Cancer
  • ​Katie Lichter, MD, University of California, San Francisco, California 
• Efficacy of COVID Vaccine on Cancer Patients
  • ​Marina Garassino, MD, University of Chicago, Chicago [M]

• Resectable versus Unresectable
  • ​Keith Naunheim, MD, St. Louis University, St. Louis, Missouri [S]
  • Elliot Wakeam, MD, University of Michigan, Ann Arbor, Michigan [S]
• Proton versus IMRT
  • Jeffrey Bradley, MD, FASTRO, Emory University School of Medicine, Atlanta [R]
  • Sue Yom, MD, PhD, FASTRO, University of California, San Francisco, San Francisco [R]

Coffee Break in the Exhibit Hall

Hot Topic: Peri-operative Therapy
Moderator: Thomas Stinchcombe, MD, Duke Cancer Center, Durham, North Carolina [M]

• Neo-adjuvant and adjuvant immunotherapy
  • ​Catherine Shu, MD, Columbia University, New York [M]
• Adjuvant Targeted therapy
  • ​Thomas Stinchcombe, MD, Duke Cancer Center, Durham, North Carolina[R]
• Post-operative Radiotherapy
  • ​Pamela Samson, MD, MPHS, Washington University School of Medicine, St. Louis [R]
• Lung SBRT Distinguishing Progression vs. Radiation Fibrosis
  • ​Jeremy Brownstein, MD, MS, The Ohio State University, Columbus, Ohio [R]
• Q&A